About Docosapentaenoic Acid (Omega-3)
Docosapentaenoic acid (DPA, 22:5 n-3) is the third major marine omega-3, structurally intermediate between EPA and DHA, and can retroconvert to EPA in the body. Unlike EPA and DHA, dedicated clinical trials are sparse — nearly all omega-3 RCT evidence comes from EPA/DHA or their combination. DPA's cardiovascular signal is largely observational (higher blood DPA correlates with lower triglycerides, inflammation, and coronary heart disease risk), with only a few small RCTs and no established DPA-specific intake target. It occurs as a minor component of fish and seal/krill oils. Not an essential nutrient with its own RDA.
What Docosapentaenoic Acid (Omega-3) supports
- Higher blood levels linked to lower heart-disease risk (observational)
- Marine omega-3 that can convert to EPA in the body
How much Docosapentaenoic Acid (Omega-3) to take
The RDA prevents deficiency. The effective range is what clinical trials used to actually move the outcome.
Effective
100–500
mg
No established DPA-specific target. Diet provides ~20–30 mg/day; supplements add 50–200 mg; trials used up to ~500 mg. Usually a minor component of fish/krill oil alongside EPA and DHA.
Clinical evidence
Limited clinical evidence. Mostly observational evidence (blood DPA ↔ lower CHD risk); few dedicated RCTs — nearly all omega-3 trial evidence is EPA/DHA
NIH Fact Sheet